Írland - enska - HPRA (Health Products Regulatory Authority)

sanofi pasteur - rabies virus (inactivated) strain wistar (pm/wi 38-1503-3m) - powder and solvent for suspension for injection in pre-filled syringe - rabies, inactivated, whole virus

Írland - enska - HPRA (Health Products Regulatory Authority)

sanofi pasteur - inactivated rabies virus strain pm/wi 38 1503 3m - powder and solvent for suspension for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - mitomycin - powder for solution for injection/infusion - 10mg

Ísrael - enska - Ministry of Health

glaxo smith kline (israel) ltd - varicella virus, live attenuated - powder and solvent for solution for injection - varicella virus, live attenuated nlt 10^3.3 pfu - varicella zoster vaccines - varilrix is intended for the active immunization against varicella of the categories of persons listed below, where there is no history of varicella.- healthy subjects, from the age of 12 months.- patients at high risk of severe varicella, such as patients with acute leukemia or a chronic condition, those on immunosuppressive therapy or those for whom an organ transplant is being considered.healthy persons living in close contact with patients with varicella and high-risk patients.

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - factor ix fraction,dried -

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - mitomycin - powder for solution for injection - 2mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - mitomycin - powder for solution for injection - 10mg

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

Singapúr - enska - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - live attenuated mycobacterium bovis (bcg) danish 1331 - injection, powder, for solution - 0.75 mg/ml - live attenuated mycobacterium bovis (bcg) danish 1331 0.75 mg/ml